Clinical trial\u901f\u5831 for regenerative medicine Redasemide targeting epidermolysis bullosa with nutritional impairment and acute phase stroke. In the additional Phase 2 trial, closure of difficult ulcers achieved in 3\/4 cases; in the global late Phase 2, primary endpoints not met, but efficacy trend and good tolerability observed. Future development plans to be pursued by Shionogi & Co., Ltd.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRIM","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4599-20260909-01.pdf","jir_short_summary":"Clinical trial\u901f\u5831 for regenerative medicine Redasemide targeting epidermolysis bullosa with nutritional impairment and acute phase stroke. In the additional Phase 2 trial, closure of difficult ulcers achieved in 3\/4 cases; in the global late Phase 2, primary endpoints not met, but efficacy trend and good tolerability observed. Future development plans to be pursued by Shionogi & Co., Ltd.","jir_summary":"### Section Heading\nThis document is an IR report that\u901f\u5831 results of regenerative\u8a98\u5c0e\u533b\u85ac\u00ae\u30ec\u30c0\u30bb\u30e0\u30c1\u30c9\u306eclinical trials. It describes results from additional Phase 2 and global late Phase 2 trials targeting nutritional impairment epidermolysis bullosa and acute phase stroke, with safety deemed favorable. In the\u8ffd\u52a0\u8a66\u9a13 for epidermolysis bullosa, the primary endpoint of refractory ulcer closure was achieved in three cases, with some improvement in systemic symptoms. In the late-stage trial for acute phase stroke, the primary endpoint was not met and the difference was not statistically significant, but there are trends toward improvement and good safety similar to domestic studies. A divestiture to Shionogi & Co., Ltd. is planned to guide future development strategy.\n\n### Second Section Heading\nThis report demonstrates ongoing R&D continuity, and going forward, development progress and analyses by Shionogi & Co., Ltd. will be used to evaluate expansion of indications for epidermolysis bullosa and acute phase stroke and clinical applications. No new safety concerns, and tolerability is judged favorable.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"","jir_key_figures":"\u91cd\u8981\u6570\u50241: \u4e0d\u660e\uff08\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u306e\u9054\u6210\u72b6\u6cc1\u306f\u8a18\u8f09\u3060\u304c\u5177\u4f53\u6570\u5024\u306f\u4e0d\u660e\uff09\n\u91cd\u8981\u6570\u50242: 4\u4f8b\u4e2d3\u4f8b\u9054\u6210\uff08\u6804\u990a\u969c\u5bb3\u578b\u8868\u76ae\u6c34\u75b1\u75c7 \u7b2c2\u76f8\u8ffd\u52a0\u8a66\u9a13\uff09\n\u91cd\u8981\u6570\u50243: 90\u65e5\u6642\u70b9\u306emRS\u3067\u6709\u610f\u5dee\u306a\u3057\uff08\u6025\u6027\u671f\u8133\u6897\u585e \u30b0\u30ed\u30fc\u30d0\u30eb\u5f8c\u671f\u7b2c2\u76f8\uff09","jir_meta_title":"\u3010\u30b9 \u30c6 \u30e0 \u30ea \u30e0\u3011\u518d\u751f\u8a98\u5c0e\u533b\u85ac\u30ec\u30c0\u30bb\u30e0\u30c1\u30c9\u306e\u81e8\u5e8a\u8a66\u9a13\u901f\u5831\uff5c2026\u5e749\u67089\u65e5","jir_meta_description":"\u518d\u751f\u8a98\u5c0e\u533b\u85ac\u30ec\u30c0\u30bb\u30e0\u30c1\u30c9\u306e\u6804\u990a\u969c\u5bb3\u578b\u8868\u76ae\u6c34\u75b1\u75c7\u304a\u3088\u3073\u6025\u6027\u671f\u8133\u6897\u585e\u3092\u5bfe\u8c61\u3068\u3057\u305f\u81e8\u5e8a\u8a66\u9a13\u901f\u5831\u3092\u5831\u544a\u3002\u8ffd\u52a0\u7b2c2\u76f8\u3067\u96e3\u6cbb\u6027\u6f70\u760d\u306e\u9589\u93963\/4\u4f8b\u3001\u5f8c\u671f\u7b2c2\u76f8\u3067\u4e3b\u8981\u6307\u6a19\u672a\u9054\u306a\u304c\u3089\u5b89\u5168\u6027\u306f\u826f\u597d\u3002\u4eca\u5f8c\u306e\u958b\u767a\u65b9\u91dd\u306f\u5869\u91ce\u7fa9\u88fd\u85ac\u304c\u6c7a\u5b9a\u4e88\u5b9a\u3002","jir_og_title":"\u518d\u751f\u8a98\u5c0e\u533b\u85ac\u30ec\u30c0\u30bb\u30e0\u30c1\u30c9\u306e\u81e8\u5e8a\u8a66\u9a13\u901f\u5831\uff5c2026\u5e749\u67089\u65e5","jir_og_description":"\u6804\u990a\u969c\u5bb3\u578b\u8868\u76ae\u6c34\u75b1\u75c7\u3068\u6025\u6027\u671f\u8133\u6897\u585e\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30ec\u30c0\u30bb\u30e0\u30c1\u30c9\u306e\u81e8\u5e8a\u8a66\u9a13\u901f\u5831\u3092\u516c\u958b\u3002\u5b89\u5168\u6027\u306f\u826f\u597d\u3067\u3001\u4eca\u5f8c\u306e\u958b\u767a\u65b9\u91dd\u6c7a\u5b9a\u3092\u5f85\u3064\u6bb5\u968e\u3067\u3059\u3002","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-111791","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n